IRCCS Foundation, National Cancer Institute, Milan, Italy.
Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Int J Gynaecol Obstet. 2019 Apr;145(1):28-33. doi: 10.1002/ijgo.12769. Epub 2019 Feb 15.
To identify predictive factors of recurrence and survival in patients with early-stage epithelial ovarian cancer (eEOC).
We retrospectively searched the medical records of all women undergoing optimal surgical staging for eEOC (stage I-II) at the National Cancer Institute of Milan, Italy, between January 1, 1974, and December 31, 2014.
During the study period, 429 patients underwent primary surgery followed by either adjuvant chemotherapy or observation alone for apparent eEOC. In multivariable analysis, International Federation for Gynecology and Obstetrics (FIGO) stage greater than 1 (hazard ratio [HR] 2.49, 95% CI 1.24-4.99) was the only prognostic factor for lower disease-free survival. Multivariate analysis showed that age at diagnosis (HR 1.68, 95% CI 1.14-2.47) and stage (HR 2.29, 95% CI 1.01-6.39) were independent predictive factors for poorer overall survival (OS).
FIGO stage is the most important prognostic factor for recurrence and survival in patients with eEOC. Furthermore, age at diagnosis was identified as a factor that negatively influenced OS. Our data for oncologic outcomes are similar to those reported in previous studies.
确定早期上皮性卵巢癌(eEOC)患者复发和生存的预测因素。
我们回顾性地检索了意大利米兰国家癌症研究所 1974 年 1 月 1 日至 2014 年 12 月 31 日期间所有接受最佳手术分期的 eEOC(I-II 期)患者的病历。
在研究期间,429 例患者接受了原发性手术,随后接受辅助化疗或单独观察治疗,用于治疗明显的 eEOC。多变量分析显示,国际妇产科联合会(FIGO)分期大于 1(风险比 [HR] 2.49,95%置信区间 1.24-4.99)是疾病无复发生存率较低的唯一预后因素。多变量分析显示,诊断时的年龄(HR 1.68,95%置信区间 1.14-2.47)和分期(HR 2.29,95%置信区间 1.01-6.39)是总生存(OS)较差的独立预测因素。
FIGO 分期是 eEOC 患者复发和生存的最重要预后因素。此外,诊断时的年龄被确定为对 OS 产生负面影响的因素。我们的肿瘤学结果数据与之前的研究报告相似。